You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
安科生物(300009.SZ)半年度淨利潤預增40%-60%
格隆匯 07-13 19:05

格隆匯7月13日丨安科生物(300009.SZ)公佈,預計2021年半年度歸屬於上市公司股東的淨利潤22732.24萬元-25979.7萬元,同比增長40%-60%。

2021半年度,公司不斷聚焦主業,提高資源配置效率,加強成本及費用的控制,並積極落實全年工作計劃,各項工作穩步推進

報吿期內,公司持續加強市場推廣工作,完善銷售渠道,公司基因工程藥中成藥、化學制劑藥產品收入繼續保持穩定增長其中主營產品重組人生長激素產品同比實現大幅增長帶動了合併淨利潤指標的增長

本期非經常性損益對淨利潤的影響金額預計約1460萬元,本期歸屬於上市公司股東扣除非經常損益後的淨利潤預計較上年同期增長45%-67%上年度同期非經常性損益對淨利潤的影響金額為1556萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account